Diagnostic Significance of Chemerin and Chitinase 3-Like Protein 1 Levels in Cholelithiasis
Abstract
Objectives: Cholelithiasis is a common gallbladder disease that refers to the formation of gallstones. In this study, we investigated the relationship between Cholelithiasis and Chitinase 3-like-1 protein (Chi3L1) and Chemerin levels.
Materials and Methods: Our study was conducted in 88 individuals, 44 of whom were healthy and 44 of whom had cholelithiasis. Chemerin and Chi3L1 serum levels were measured by enzyme-linked immunsorbent assay-ELISA method. The results were then analyzed using SPSS.
Results: When cholelithiasis patient groups were compared with healthy groups, a significant increase was found in Chemerin levels in cholelithiasis patients (6.28-4.68, p<0.001). Chi3L1 concentration values were not statistically different between groups (p=0.460). After receiver operating characteristic analysis, the Chemerin result was statistically significant in predicting disease [p<0.001, area under the curve: 0.795 (0.697-0.893)], Chi3L1 was statistically insignificant in predicting disease. While the difference between the patient and control groups in terms of creatinine,albumin, amylase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase, direct bilirubin, sodium, and calcium was statistically significant (p<0.05), the difference between Chi3L1 concentration and creatinine and total protein was statistically significant (p<0.05).
Conclusion: Our study suggests that chemerin may be a new biomarker in the diagnosis of cholelithiasis. In addition, since our study has not been done before, it can bring a new perspective to the literature.
Key Words: Cholelithiasis, Chemerin, Chitinase 3-Like-1
Keywords
References
- 1. Seddighi S, Ghidari ME, Sadeghi A, et al. Evaluation of the cardiovascular risk in patients with biliary stones: a descriptive cross-sectional study. Gastroenterol Hepatol Bed Bench. 2018;11(Suppl 1):S14-S19.
- 2. Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. F1000Res. 2018;7:F1529.
- 3. Brighi N, Lamberti G, Maggio I, et al. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Dig Liver Dis. 2019;51:689-694.
- 4. Panpimanmas S, Manmee C. Risk factors for gallstone disease in a Thai population. J Epidemiol. 2009;19:116-121.
- 5. Chen LY, Qiao QH, Zhang SC, et al. Metabolic syndrome and gallstone disease. World J Gastroenterol. 2012;18:4215-4220.
- 6. Sun H, Tang H, Jiang S, et al. Gender and metabolic differences of gallstone diseases. World J Gastroenterol. 2009;15:1886-1891.
- 7. Almario CV, Ballal ML, Chey WD, et al. Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans. Am J Gastroenterol. 2018;113:1701-1710.
- 8. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep. 2005;7:132-140.
- 9. Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic gallstones. Br J Surg. 2004;91:734-738.
- 10. İlhan M, İlhan G, Gök AFK, et al. The course and outcomes of complicated gallstone disease in pregnancy: Experience of a tertiary center. Turk J Obstet Gynecol. 2016;13:178-182.